Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for Windows
2,225 results
  • Extracellular RNA in Central Nervous System Pathologies. [Review]
    Front Mol Neurosci 2019; 12:254Tielking K, Fischer S, … Xu R
  • The discovery of extracellular RNA (exRNA) has shifted our understanding of the role of RNA in complex cellular functions such as cell-to-cell communication and a variety of pathologies. ExRNAs constitute a heterogenous group of RNAs ranging from small (such as microRNAs) and long non-coding to coding RNAs or ribosomal RNAs. ExRNAs can be liberated from cells in a free form or bound to proteins a…
  • [Interleukin-33: Friend or Enemy in the Fight against Tumors?] [Review]
    Mol Biol (Mosk) 2019 Sep-Oct; 53(5):774-789Gorbacheva AM, Mitkin NA
  • Interleukin-33 (IL-33) belongs to the IL-1 cytokine family and acts as a danger signal. IL-33 is released from stressed or necrotic cells. Initially, IL-33 was described as an inducer of the humoral immune response, which activated Th2 cells and mast cells involved in modulating inflammation and allergic reactions. In addition, IL-33 acts as a stimulator of the Th1, NK, and CD8T cells, which indu…
  • U3-1402 sensitizes HER3-expressing tumors to PD-1 blockade by immune activation. [Journal Article]
    J Clin Invest 2019Haratani K, Yonesaka K, … Nakagawa K
  • Immunotherapy targeting programmed cell death-1 (PD-1) induces durable antitumor efficacy in many types of cancer. However, such clinical benefit is limited because of the insufficient reinvigoration of antitumor immunity with the drug alone; therefore, rational therapeutic combinations are required to improve its efficacy. In our preclinical study, we evaluated the antitumor effect of U3-1402, a…
  • Methotrexate an Old Drug with New Tricks. [Review]
    Int J Mol Sci 2019; 20(20)Bedoui Y, Guillot X, … Gasque P
  • Methotrexate (MTX) is the first line drug for the treatment of a number of rheumatic and non-rheumatic disorders. It is currently used as an anchor disease, modifying anti-rheumatic drug in the treatment of rheumatoid arthritis (RA). Despite the development of numerous new targeted therapies, MTX remains the backbone of RA therapy due to its potent efficacy and tolerability. There has been also a…
New Search Next